Email this article USE OF ZONISAMIDE (ZONEGRAN) IN THE TREATMENT OF EPILEPSY: EMPHASIS ON MONOTHERAPY OF FOCAL SEIZURES (A REVIEW OF FOREIGN LITERATURE)
- Authors: Pylaeva O.A.1, Mukhin K.Y.1
-
Affiliations:
- Saint Lukа’s Institute of Child Neurology and Epilepsy, Moscow
- Issue: Vol 9, No 2 (2014)
- Pages: 42-49
- Section: REVIEWS AND LECTURES
- Published: 18.04.2015
- URL: https://rjdn.abvpress.ru/jour/article/view/21
- DOI: https://doi.org/10.17650/2073-8803-2014-9-2-42-49
- ID: 21
Cite item
Full Text
Abstract
Despite a considerable advance made in epileptology, resistant epilepsies are about 30 % among all epilepsy types. The paper reviews the current literature dealing with the efficacy and safety of the new antiepileptic drug zonisamide (Zonegran) in the treatment of epilepsy. It describes the mechanism of action, pharmacokinetics, efficacy, and tolerability of zonisamide in resistant epilepsy. The authors focus their attention on recent trials of zonisamide used in monotherapy.
Keywords
About the authors
O. A. Pylaeva
Saint Lukа’s Institute of Child Neurology and Epilepsy, Moscow
Author for correspondence.
Email: olgapylaeva@yandex.ru
Russian Federation
K. Yu. Mukhin
Saint Lukа’s Institute of Child Neurology and Epilepsy, Moscow
Email: fake@neicon.ru
Russian Federation
References
Supplementary files
